Evidence map›Paper›PMID 20943885›Full record

ArticleBrain : a journal of neurology2011

Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy.

Carla Giordano, Monica Montopoli, Elena Perli, Maurizia Orlandi, Marianna Fantin, Fred N Ross-Cisneros, Laura Caparrotta, Andrea Martinuzzi, Eugenio Ragazzi, Anna Ghelli and 3 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01267422 (Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy), which is not on this map. Cited by 120 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01267422 nacompletednot on this map

Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy

TypeinterventionalSponsorBin LiRan2011 to 2015Enrolled9ConditionsLeber Hereditary Optic NeuropathyArmsrAAV2-ND4
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 243 citations in OpenAlex.

  1. The Role of Estrogen in Mitochondrial Disease.Cellular and molecular neurobiology · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. [Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Carla GiordanoDipartimento di Medicina Sperimentale e Patologia, Sapienza, Universita` di Roma, 00161 Rome, Italy.
Monica Montopoli
Elena Perli
Maurizia Orlandi
Marianna Fantin
Fred N Ross-Cisneros
Laura Caparrotta
Andrea Martinuzzi
Eugenio Ragazzi
Anna Ghelli
Alfredo A Sadun
Giulia d'Amati
Valerio Carelli
Sapienza University of Rome · ITUniversity of Padua · ITIRCCS Eugenio Medea · ITSouthern California University for Professional Studies · USUniversity of Bologna · ITUniversity of Southern California · US

Funding

VISION RESEARCHP30EY003040 · NEI · DOHENY EYE INSTITUTE · PI SUN, DEMING · 1985 to 2013
$7.0M
NEI NIH HHS EY03040Telethon GGP06233
6 · The paper itself

Abstract

Leber's hereditary optic neuropathy, the most frequent mitochondrial disease due to mitochondrial DNA point mutations in complex I, is characterized by the selective degeneration of retinal ganglion cells, leading to optic atrophy and loss of central vision prevalently in young males. The current study investigated the reasons for the higher prevalence of Leber's hereditary optic neuropathy in males, exploring the potential compensatory effects of oestrogens on mutant cell metabolism. Control and Leber's hereditary optic neuropathy osteosarcoma-derived cybrids (11778/ND4, 3460/ND1 and 14484/ND6) were grown in glucose or glucose-free, galactose-supplemented medium. After having shown the nuclear and mitochondrial localization of oestrogen receptors in cybrids, experiments were carried out by adding 100 nM of 17β-oestradiol. In a set of experiments, cells were pre-incubated with the oestrogen receptor antagonist ICI 182780. Leber's hereditary optic neuropathy cybrids in galactose medium presented overproduction of reactive oxygen species, which led to decrease in mitochondrial membrane potential, increased apoptotic rate, loss of cell viability and hyper-fragmented mitochondrial morphology compared with control cybrids. Treatment with 17β-oestradiol significantly rescued these pathological features and led to the activation of the antioxidant enzyme superoxide dismutase 2. In addition, 17β-oestradiol induced a general activation of mitochondrial biogenesis and a small although significant improvement in energetic competence. All these effects were oestrogen receptor mediated. Finally, we showed that the oestrogen receptor β localizes to the mitochondrial network of human retinal ganglion cells. Our results strongly support a metabolic basis for the unexplained male prevalence in Leber's hereditary optic neuropathy and hold promises for a therapeutic use for oestrogen-like molecules.

Indexed as

Analysis of VarianceApoptosisBlotting, WesternCell LineDNA, MitochondrialEstradiolEstrogensHumansImmunohistochemistryMaleMembrane Potential, MitochondrialMitochondriaOptic Atrophy, Hereditary, LeberOxidative StressReactive Oxygen SpeciesRetinal Ganglion CellsDNA, MitochondrialEstradiolEstrogensReactive Oxygen SpeciesSuperoxide DismutaseSuperoxide Dismutase 2

Identifiers

PMID20943885
PMCPMC3025718
OpenAlexW2101656247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.